White Patients Have Longest Survival Time in Cutaneous Melanoma

Share this content:
For patients with cutaneous melanoma, whites have the longest survival time.
For patients with cutaneous melanoma, whites have the longest survival time.

(HealthDay News) -- For patients with cutaneous melanoma, whites have the longest survival time, according to a study published in the Journal of the American Academy of Dermatology.

Sean M. Dawes, M.P.H., from the Michigan State University College of Osteopathic Medicine in East Lansing, and colleagues examined survival across racial groups in patients with malignant melanoma. Data were included from the Surveillance, Epidemiology, and End Results database for 96,953 patients with a diagnosis of cutaneous melanoma as their primary cancer from 1992 to 2009.

The researchers found that white patients had the longest survival time, followed by Hispanic, Asian-American/Native-American/Pacific-Islander, and black patients. After stratification by race and stage, blacks had significantly lower survival for stages I and III (P < 0.05), with increased hazard ratios of 3.037 and 1.864, respectively. Compared with whites, blacks had a greater proportion of later-stage cutaneous melanoma.

RELATED: For First-line Therapy of BRAF-mutant Melanoma, PD-1 Inhibitors May Be Preferred

"Despite higher incidence of cutaneous melanoma in whites, overall survival for cutaneous melanoma in non-whites was significantly lower," the authors write. "Our results suggest that more emphasis is needed for melanoma screening and awareness in non-white populations to improve survival outcome."

Reference

  1. Dawes SM, Tsai S, Gittleman H, et al. Racial disparities in melanoma survival. JAAD. 2016 Jul 28. doi: http://dx.doi.org/10.1016/j.jaad.2016.06.006. [Epub ahead of print.]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters